Patent · US Active

Pyrimidine-2,4-diamine derivatives for treatment of cancer

US9944640B2 · kind B2 · utility

1Cited by

3References

25Claims

0Family size

Assignee

THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING · SE

Inventors

Martin Scobie · Uppsala, SE
Thomas Helleday · Stockholm, SE
Tobias Koolmeister · Stockholm, SE
Sylvain Jacques · Val-de-Reuil, FR
Matthieu Desroses · Knivsta, SE
Marie-Caroline Jacques-Cordonnier · Val-de-Reuil, FR

Key dates

Filing date	Mar 2, 2017
Grant date	Apr 17, 2018
Priority date	—
Expiry date	Mar 2, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/05
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A compound of formula I,or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.